The earnings miss and year-over-year revenue decline are likely to negatively impact investor sentiment towards HOOKIPA Pharma in the short term. Historically, earnings misses can lead to a decrease in stock price, as seen in the company's past performance where a beat in EPS estimates led to a stock price increase. The significant miss in EPS and the decline in revenue highlight potential operational or market challenges the company may be facing.